Sunday 25 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • New medicines recommended for approval by CHMP in April 2025

New medicines recommended for approval by CHMP in April 2025

Pharmaceutical
26 April 2025

The European Medicines Agency’s (EMA)) human medicines committee (CHMP) has recommended seven novel medicines for approval at its April 2025 meeting. A final decision from the European Commission is usually issued in about two months.

The CHMP recommended granting a marketing authorization for Vertex Pharmaceuticals’ (Nasdaq: VRTX) Alyftrek (deutivacaftor / tezacaftor / vanzacaftor), a medicine intended for the treatment of cystic fibrosis in people aged six years and older who have at least one non class I mutation in the cystic fibrosis transmembrane conductance regulator gene. Cystic fibrosis is an inherited disease that damages the lungs, the digestive system and other organs.

A positive opinion was adopted for Purpose Pharma International’s Attrogy (diflunisal), for the treatment of hereditary transthyretin-mediated amyloidosis, a disease in which abnormal proteins called amyloids build up in tissues around the body including around the nerves.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Gilead says Trodelvy ASCENT-03 study meets primary endpoint
Pharmaceutical
Gilead says Trodelvy ASCENT-03 study meets primary endpoint
24 May 2025
Pharmaceutical
Reshaping HIV – how the journey from daily pills to long-acting therapies could take us closer to ending the HIV epidemic
23 May 2025
Biotechnology
Ionis’ olezarsen shows new promise with strong Phase III results
23 May 2025
Pharmaceutical
Verastem expands ambitions with strong pancreatic cancer data at ASCO
23 May 2025
Pharmaceutical
May batch of novel medicines recommended for approval by CHMP
23 May 2025
Pharmaceutical
MHRA approves Akantior to treat acanthamoeba keratitis
23 May 2025
Pharmaceutical
Relief value doubles on FDA designation
23 May 2025

Company Spotlight

An American biotech company developing solutions that treat urothelial and specialty cancers.




More Features in Pharmaceutical

Gilead says Trodelvy ASCENT-03 study meets primary endpoint
24 May 2025
Reshaping HIV – how the journey from daily pills to long-acting therapies could take us closer to ending the HIV epidemic
23 May 2025
Verastem expands ambitions with strong pancreatic cancer data at ASCO
23 May 2025
May batch of novel medicines recommended for approval by CHMP
23 May 2025


The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze